These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8549297)
1. Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period. Segreti J; Connelly R Drugs; 1995; 49 Suppl 2():185-7. PubMed ID: 8549297 [No Abstract] [Full Text] [Related]
2. The future of the quinolones. Andriole VT Drugs; 1999; 58 Suppl 2():1-5. PubMed ID: 10553697 [TBL] [Abstract][Full Text] [Related]
3. Major advances in antibacterial quinolone therapy. Neu HC Adv Pharmacol; 1994; 29A():227-62. PubMed ID: 7826861 [No Abstract] [Full Text] [Related]
4. The antimicrobial activity of sparfloxacin, a new quinolone. Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316 [No Abstract] [Full Text] [Related]
5. Bacterial resistance to the quinolone antimicrobial agents. Hooper DC; Wolfson JS Am J Med; 1989 Dec; 87(6C):17S-23S. PubMed ID: 2690616 [TBL] [Abstract][Full Text] [Related]
6. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections]. Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429 [TBL] [Abstract][Full Text] [Related]
7. [Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group]. Fujiue Y; Kuwabara M; Muroki K; Kohara T; Itaha H; Yamasaki M; Sasaki M; Onimura K; Shigemitsu M; Kashiyama S Jpn J Antibiot; 2000 Jun; 53(6):409-21. PubMed ID: 10955237 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of broad spectrum quinolones against clinical bacterial isolates. Matsumoto T; Tateda K; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K Drugs; 1995; 49 Suppl 2():219-21. PubMed ID: 8549309 [No Abstract] [Full Text] [Related]
10. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity. Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869 [TBL] [Abstract][Full Text] [Related]
11. [The new quinolones]. Lontie M J Pharm Belg; 1989; 44(4):292-301. PubMed ID: 2691640 [TBL] [Abstract][Full Text] [Related]
12. [In vitro evaluation of lomefloxacin]. Dette GA; Knothe H Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672 [TBL] [Abstract][Full Text] [Related]
13. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Frère P; Hermanne JP; Debouge MH; Fillet G; Beguin Y Bone Marrow Transplant; 2002 Apr; 29(7):589-94. PubMed ID: 11979308 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW; Acar JF Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361 [TBL] [Abstract][Full Text] [Related]
15. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates. Barry AL; Fuchs PC; Brown SD Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655 [TBL] [Abstract][Full Text] [Related]